Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 20, 2026.

Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors

Shuhang Wang, Jingwei Sun, Kun Chen and 8 more

BMC Medicine · 2021 · Review · CC BY

doi:10.1186/s12916-021-02006-4

Abstract

Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to treat patients. Its diverse TCR clonality, superior tumor-homing ability, and low off-target toxicity endow TIL therapy unique advantages in treating solid tumors compared with other adoptive cellular therapies. Nevertheless, the successful application of TIL therapy currently is still limited to several types of tumors. Herein in this review, we summarize the fundamental work in the field of TIL therapy and the current landscape and advances of TIL clinical trials worldwide. Moreover, the limitations of the current TIL regimen have been discussed and the opportunities and challenges in the development of next-generation TIL are highlighted. Finally, the future directions of TIL therapy towards a broader clinical application have been proposed.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 20, 2026. Paragraph numbers are ours, so an answer can point at one.

A historical perspective of TIL therapy

TIL therapy is a type of adoptive cellular therapy leveraging the patient’s own immune system to treat tumors. In TIL therapy, TIL is isolated from the tumor site by biopsy or surgery, stimulated and expanded to a large number in vitro with interleukin-2 (IL-2), and then infused back into the patient. In 1982, the pioneer in this field, Dr. Steven Rosenberg, and colleagues at the National Institutes of Health (NIH) isolated TIL from multiple mouse tumor models for the first time, and later demonstrated that the combination of cyclophosphamide conditioning, TIL and simultaneous IL-2 administration cured 100% of mice with hepatic metastases and 50% with pulmonary metastases in a MC38 colon adenocarcinoma model, laying the foundation for the application of TIL in the treatment of advanced cancers in human. The earliest attempt of TIL therapy in the clinic can be traced back to 1988 and achieved a 60% objective response rate (ORR) in metastatic melanoma.

The process of generating TIL usually starts from a pre-rapid expansion phase (pre-REP), where TIL is dissociated from or emigrates out of the tumor fragments and goes through preliminary amplification. Then TIL is further expanded in a rapid expansion phase (REP) in response to stimulators, such as IL-2 and/or feeder cells. The traditional procedure of TIL production is assayed for specific tumor recognition and usually takes 6–8 weeks. However, TIL is prone to exhaustion after long-time culturing in vitro and could not persist for long in patients. Besides, the low successful rate of growing autologous tumors in vitro led to a more than 50% dropout rate of patients referred for TIL therapy, largely limiting its clinical application. To this end, Dr. Rosenberg and others developed a “Young TIL” approach that rapidly expands TIL for administration without in vitro selection for tumor reactivity, which markedly improves the timeliness of TIL production as well as its survival and efficacy in vivo (Fig. 1). Later on, “Young TIL” has shown comparable clinical outcome with traditional TIL in melanoma patients. Besides, the effects of different T cell functional modulators and cytokines on TIL manufacture have also been examined. It has been shown that anti-PD-1, anti-41BB, or anti-CTLA-4 can increase TIL expansion. Combination of IL-2/15/21 can enhance TIL expansion in lung and colorectal cancer and promote CD8+ T cell percentage as well as TCR clone diversity compared to IL-2 alone.

Currently, the most widely-used TIL production method is to isolate infiltrating lymphocytes from tumor tissues and then culture and expand these cells in vitro. Previous studies showed that tumor-specific T cells can only be found in the peripheral blood at a minimal level post treatment with PD-1 antibodies, but barely detected before the treatment. Although some researchers isolated PD-1+ T cells from the peripheral blood mononuclear cells (PBMCs) and tried to define them as tumor-specific T cells, later studies demonstrated that the percentage of PD-1+ T cells in the PBMCs is actually similar between cancer patients and healthy donors, but highly elevated in the lymphocytes infiltrated in tumors. Besides, the PBMCs from both healthy donors and patients contain large numbers of virus-specific T cells, further potentiating the rationality of collecting tumor-specific T cells from tumors as the raw material for TIL production.

Distinguishing features of TIL therapy in solid tumors and the current advances of clinical trials

The following attributes of solid tumor may impose major challenges for developing effective adoptive cellular therapies. Different from hematological malignancies with lineage markers, the high heterogeneity of solid tumors makes it hard to find an ideal target for all tumor cells. Targeting single tumor antigen usually leads to antigen loss or recurrence of more aggressive clones. Moreover, a large percentage of solid tumors is hard to be infiltrated even upon adoptive transfer of a large number of T cells. In addition, it is difficult for T cells to fully exert their function in the tumor microenvironment (TME) due to multiple immune suppressive mechanisms, including but not limited to the upregulation of immune inhibitory molecules, cytokines and metabolites, downregulation of co-stimulatory molecules, and the presence of immune regulatory subsets, such as Tregs, myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs).

TIL may hold some distinguishing advantages for treating solid tumors. Firstly, TIL is composed of T cells with multiple T cell receptor (TCR) clones capable of recognizing an array of tumor antigens, and therefore may be superior in tackling the tumor heterogeneity compared to other adoptive cellular therapies, such as chimeric antigen receptor T (CAR-T) and TCR-T cell therapy. In line with this, TIL has demonstrated better clinical efficacy than CAR-T in solid tumors containing high mutation load, such as melanoma. Secondly, having been stimulated by tumor antigens in vivo, TIL tends to dominantly consist of effect memory T (Tem) cells, which express chemokine receptors on the surface, such as CCR5 and CXCR3. Together with their tumor-specific TCRs, TIL can easily home to antigenically distinct tissues, including tumors, after transferred into patients. Last but not least, off-target toxicity has seldom been reported in TIL therapy probably due to the negative selection of TCRs of TIL during the early development of T cell immunity. On the contrary, the engineered tumor-targeting single-chain variable fragments (scFv) in CAR-T or affinity-enhanced TCR in TCR-T product may lead to toxicity if they bear cross-reactivity with antigens on normal tissues.

In recent years, there have been 79 trials of TIL therapy including 22 kinds of TIL products between 2011 and 2020 (Fig. 2). The trial numbers peaked in 2018 and 2019, along with the success of two phase II trials of TIL products LN144 and LN145 by Iovance in 2018. Currently, 54% (43/79) trials are open, 17% (13/79) have been completed and the rest are either closed or terminated (Fig. 3). Geographic analysis shows that 51% (40/79) of these trials are in the USA and 15% (12/79) are in China (Fig. 3). TIL therapy has mainly been tested as the second treatment line (Fig. 4). Melanoma is still the top tumor type with most clinical trials, followed by non-small cell lung cancer (NSCLC), ovarian cancer, and head and neck cancer (Fig. 4). So far, TIL therapy has shown impressive clinical benefits in metastatic melanoma and advanced cervical cancer, even in patients treated with checkpoint inhibitors. Preliminary efficacy has also been demonstrated in NSCLC, colorectal cancer (CRC), and breast cancer. The administration of high-dose IL-2 used as standard of care to support the growth and activity of infused TIL, however, may restrain the clinical application of TIL therapy. High-dose IL-2 oftentimes induces systemic toxicity that requires intensive monitoring and care, and could also promote regulatory T cells that suppress the anti-tumor response of TIL. Although a more than 30% ORR can be achieved in trials with low or intermediate dose of IL-2, most TIL trials still go with high-dose IL-2 infusion. Furthermore, unsustained persistence in vivo and immune suppression in the harsh TME are also obstacles to achieve the maximal outcome of TIL therapy.

Development of next-generation TIL therapy

To reduce toxicities associated with high-dose IL-2 as well as improve the in vivo survival and function of the traditional TIL therapy, next-generation TIL product is under active investigation. Next-generation TIL is genetically modified TIL to either overexpress a gene of interest by viral transduction or knock out (KO) the target gene with technologies like CRISPR or TALEN. However, the development of next-generation TIL may face some major challenges. Gene editing can be technically difficult to achieve in TIL probably due to the varied cellular composition and growth rates of TIL compared with PBMC. Forget et al. has described a method to transduce TIL by retrovirus, leading to transduction efficiency ranging from ~ 31 to ~ 58% in TIL from metastatic melanoma and successful expansion to clinically relevant numbers, but high variability of transduction and expansion rate were observed among patients. Moreover, it is critical but challenging to select the appropriate genes to be targeted in TIL.

So far, the attempts of next-generation TIL in the clinic mainly focused on engineering TIL to overexpress cytokines, such as IL-2 and IL-12. In a phase I/II trial, IL-2 insertion into TIL showed enhanced survival in vitro after IL-2 withdraw but little improvement of persistence in vivo and clinical efficacy. Only 2/12 (17%) ORR was observed in patients who received IL-2 transduced TIL compared to ~ 50% ORR with non-modified TIL along with high-dose IL-2. Another phase I trial using TIL transduced with IL-12 expressed under the control of a nuclear factor of activated T cells (NFAT)-inducible promoter showed favorable clinical efficacy in metastatic melanoma—63% ORR was achieved in patients treated with 0.3−3e9 NFAT-IL-12 engineered TILs, which is 10–100-fold less than the cell number used in the traditional TIL therapy. However, unexpected high level of IL-12 and IFN-γ in the serum together with significant toxicity was also observed. On the other hand, the feasibility and functionality of genetically KO of T cell negative regulators in TIL, such as PD-1 and CISH, is also being actively tested at pre-clinical stage. How to rationally select or identify the target genes conveying the most benefits for TIL therapy still remains to be explored. In this regard, screening using CRISPR technologies, including CRISPR KO, interference (CRISPRi) or activation (CRISPRa), may be promising strategies to identify novel targets for TIL. Moreover, comprehensive safety and function evaluation of genetically modified TIL is required before moving into the clinic. In addition to in vitro characterization, animal models remain to be established to better understand the persistence, function as well as toxicity of modified TIL in vivo.

Conclusions

Cancer immunotherapy represented by checkpoint inhibitors, especially anti-PD-1/PD-L1 antibodies, and adoptive cellular therapies, such as CAR-T and TCR-T, has revolutionized the field of cancer treatment and significantly prolonged the survival of patients with advanced cancers. However, the response rate is still limited in most cancer types, especially solid tumors, which calls for the development of alternative therapeutic strategies. TIL holds some unique advantages in tackling solid tumors, but the laborious, expensive, and time-consuming tissue collection and production process makes TIL only be developed at some leading research institutions and companies in a few countries. There is still considerable room for further improvement and a broader application of this therapeutic approach, for instance, how to establish a standardized and stable production process of TIL from different patients, how to tailor the process based on the features of different tumor types, how to enrich tumor-specific TIL without largely increasing the process time, and how to select prognosis markers to identify patients that potentially benefit the most.

The development of gene-modified TIL holds promise to enhance the clinical outcome of TIL therapy across more indications as well as to enhance safety by decreasing the dependence on high-dose IL-2 infusion and lymphodepletion. Nevertheless, target selection and comprehensive functional evaluation could be critical steps for a successful next-generation product. On the other hand, the combination of TIL therapy with anti-PD-1/PD-L1 antibodies that blockade the immune suppression mediated by the PD pathway at the tumor site showed preliminary favorable outcomes in some recent trials. Other combinational approaches, such as TIL therapy combined with oncolytic viruses, are also under exploration. Similar to CAR-T therapies that show excellent responses in the second- or the third-line setting, there is considerable interest in moving TIL therapy to first-line treatment. The blossom of novel drug investigation at the neoadjuvant and adjuvant stage of treatment also brings opportunity to TIL. Although the development of TIL therapy is currently still in its infancy in China, the advent of CAR-T therapy has helped build a good macro-environment for cell therapy and gene editing industry. The collaboration and joint efforts from research institutions, biotech companies, hospitals as well as the government would drive this field ahead and facilitate the application of TIL therapy to a broader population of patients with solid tumors.

References 60

  1. 1.

    Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676-1680.

    Not in our library10.1056/nejm198812223192527

  2. 2.

    Eberlein TJ, Rosenstein M, Rosenberg SA. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med. 1982;156(2):385-397.

    Not in our library10.1084/jem.156.2.385

  3. 3.

    Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318-1321.

    Not in our library10.1126/science.3489291

  4. 4.

    Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 2005;28(3):258-267.

    Not in our library10.1097/01.cji.0000158855.92792.7a

  5. 5.

    Powell DJ, Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood. 2005;105(1):241-250.

    Not in our library10.1182/blood-2004-06-2482

  6. 6.

    Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26(4):332-342.

    Not in our library10.1097/00002371-200307000-00005

  7. 7.

    Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J. 2012;18(2):160-175.

    Not in our library10.1097/ppo.0b013e31824d4465

  8. 8.

    Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008;31(8):742-751.

    Not in our library10.1097/cji.0b013e31818403d5

  9. 9.

    Donia M, Junker N, Ellebaek E, Andersen MH, Straten PT, Svane IM. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. Scand J Immunol. 2012;75(2):157-167.

    Not in our library10.1111/j.1365-3083.2011.02640.x

  10. 10.

    Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol. 2013;31(17):2152-2159.

    Not in our library10.1200/jco.2012.46.6441

  11. 11.
    Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors · 2016
    No notice
  12. 12.

    Friese C, Harbst K, Borch TH, Westergaard MCW, Pedersen M, Kverneland A, et al. CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+) tumor-infiltrating lymphocytes in ovarian cancer. Sci Rep. 2020;10(1):3914.

    Not in our library10.1038/s41598-020-60738-4

  13. 13.

    Frank L, Simpson AM, Lotze M, Ritthipichai K, Mosychuk C. The T-cell Growth Factor Cocktail IL-2/IL-15/IL-21 Enhances Expansion and Effector Function of Tumor-Infiltrating T cells in a Novel Process Developed by Iovance. Society for Immunotherapy of Cancer. 2017.

    Not in our library

  14. 14.

    Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413.

    Not in our library10.1126/science.aan6733

  15. 15.

    Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018;378(21):1976-1986.

    Not in our library10.1056/nejmoa1716078

  16. 16.

    Davidson TB, Lee A, Hsu M, Sedighim S, Orpilla J, Treger J, et al. Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. Clin Cancer Res. 2019;25(6):1913-1922.

    Not in our library10.1158/1078-0432.ccr-18-1176

  17. 17.

    Jedema I, van de Meent M, Pots J, Kester MG, van der Beek MT, Falkenburg JH. Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells. Haematologica. 2011;96(8):1204-1212.

    Not in our library10.3324/haematol.2010.039099

  18. 18.

    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.

    Not in our library10.1016/j.cell.2011.02.013

  19. 19.

    Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.

    Not in our library10.1126/science.1235122

  20. 20.

    Galluzzi L, Chan TA, Kroemer G, Wolchok JD, Lopez-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10:459.

    Not in our library10.1126/scitranslmed.aat7807

  21. 21.

    Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med. 2019;25(9):1341-1355.

    Not in our library10.1038/s41591-019-0564-6

  22. 22.

    Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168(4):707-723.

    Not in our library10.1016/j.cell.2017.01.017

  23. 23.

    Anderson KG, Stromnes IM, Greenberg PD. Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell. 2017;31(3):311-325.

    Not in our library10.1016/j.ccell.2017.02.008

  24. 24.

    Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69-74.

    Not in our library10.1126/science.aaa4971

  25. 25.

    Titov A, Zmievskaya E, Ganeeva I, Valiullina A, Petukhov A, Rakhmatullina A, et al. Adoptive Immunotherapy beyond CAR T-Cells. Cancers (Basel). 2021;13:4.

    Not in our library10.3390/cancers13040743

  26. 26.

    Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer. 2013;109(9):2412-2423.

    Not in our library10.1038/bjc.2013.557

  27. 27.

    Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015;6:7458.

    Not in our library10.1038/ncomms8458

  28. 28.

    van Kooyk Y, van de Wiel-van Kemenade P, Weder P, Kuijpers TW, Figdor CG. Enhancement of LFA-1-mediated cell adhesion by triggering through CD2 or CD3 on T lymphocytes. Nature. 1989;342(6251):811-813.

    Not in our library10.1038/342811a0

  29. 29.

    Burbach BJ, Medeiros RB, Mueller KL, Shimizu Y. T-cell receptor signaling to integrins. Immunol Rev. 2007;218:65-81.

    Not in our library10.1111/j.1600-065x.2007.00527.x

  30. 30.

    Mirenda V, Jarmin SJ, David R, Dyson J, Scott D, Gu Y, et al. Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. Blood. 2007;109(7):2968-2977.

    Not in our library10.1182/blood-2006-10-050724

  31. 31.

    Sackstein R, Schatton T, Barthel SR. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Lab Invest. 2017;97(6):669-697.

    Not in our library10.1038/labinvest.2017.25

  32. 32.

    Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5(197):197ra03.

    Not in our library10.1126/scitranslmed.3006034

  33. 33.

    Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133-151.

    Not in our library10.1097/cji.0b013e3182829903

  34. 34.

    Sarnaik A, Khushalani N, Chesney J, Kluger H, Curti B, Lewis K, et al. P865 Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update. J ImmunoTher Cancer. 2020;8(Suppl 1):A12-A1A.

    Not in our library10.1136/lba2019.18

  35. 35.

    Sarnaik A, Khushalani NI, Chesney JA, Lewis KD, Medina TM, Kluger HM, et al. Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies. J Clin Oncol. 2020;38(15_suppl):10006.

    Not in our library10.1200/jco.2020.38.15_suppl.10006

  36. 36.

    Jazaeri AA, Zsiros E, Amaria RN, Artz AS, Edwards RP, Wenham RM, et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. J Clin Oncol. 2019;37(15_suppl):2538.

    Not in our library10.1200/jco.2019.37.15_suppl.2538

  37. 37.

    Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550-4557.

    Not in our library10.1158/1078-0432.ccr-11-0116

  38. 38.

    Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543-1550.

    Not in our library10.1200/jco.2014.58.9093

  39. 39.

    Sarnaik A, Khushalani NI, Chesney JA, Kluger HM, Curti BD, Lewis KD, et al. Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1. J Clin Oncol. 2019;37(15_suppl):2518-.

    Not in our library

  40. 40.

    Creelan B, Wang C, Teer J, Toloza E, Mullinax J, Yao J, et al. Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial. Cancer Res. 2020;80(16 Supplement):CT056-CT.

    Not in our library

  41. 41.

    Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016;375(23):2255-2262.

    Not in our library10.1056/nejmoa1609279

  42. 42.

    Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724-730.

    Not in our library10.1038/s41591-018-0040-8

  43. 43.

    Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-2116.

    Not in our library10.1200/jco.1999.17.7.2105

  44. 44.

    Schwartz RN, Stover L, Dutcher JP. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park). 2002;16(11 Suppl 13):11-20.

    Not in our library

  45. 45.

    Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 1986;58(12):2764-2772.

    Not in our library10.1002/1097-0142(19861215)58:12<2764::aid-cncr2820581235>3.0.co;2-z

  46. 46.

    Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, et al. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood. 2012;119(24):5688-5696.

    Not in our library10.1182/blood-2011-10-386482

  47. 47.
    Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients · 2012
    No notice
  48. 48.

    Andersen R, Donia M, Borch TH, Steensgaard EE, Iversen TZ, Kongsted P, et al. Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma. J ImmunoTher Cancer. 2014;2:S3.

    Not in our library10.1186/2051-1426-2-s3-p1

  49. 49.

    Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004;173(12):7125-7130.

    Not in our library10.4049/jimmunol.173.12.7125

  50. 50.

    Forget MA, Tavera RJ, Haymaker C, Ramachandran R, Malu S, Zhang M, et al. A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified. Tumor-Infiltrating Lymphocytes. Front Immunol. 2017;8:908.

    Not in our library10.3389/fimmu.2017.00908

  51. 51.

    Heemskerk B, Liu K, Dudley ME, Johnson LA, Kaiser A, Downey S, et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther. 2008;19(5):496-510.

    Not in our library10.1089/hum.2007.0171

  52. 52.

    Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res. 2015;21(10):2278-2288.

    Not in our library10.1158/1078-0432.ccr-14-2085

  53. 53.

    Ritthipichai K, Machin M, Lakshmipathi S, Juillerat A, Poirot L, Fardis M, et al. Genetic Modification of Iovance’s TIL through TALEN-mediated knockout of PD-1 as a strategy to empower TIL therapy for cancer. Eur Soc Med Oncol Congress. 2020.

    Not in our library

  54. 54.

    Palmer DC, Webber BR, Patel Y, Johnson MJ, Kariya CM, Lahr WS, et al. Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade. bioRxiv. 2020:2020.09.24.306571.

    Not in our library10.1016/j.medj.2022.07.008

  55. 55.

    Shifrut E, Carnevale J, Tobin V, Roth TL, Woo JM, Bui CT, et al. Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function. Cell. 2018;175(7):1958-1971.

    Not in our library10.1016/j.cell.2018.10.024

  56. 56.

    Dong MB, Wang G, Chow RD, Ye L, Zhu L, Dai X, et al. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. Cell. 2019;178(5):1189-1204.

    Not in our library10.1016/j.cell.2019.07.044

  57. 57.

    Couzin-Frankel J. Breakthrough of the year 2013. Cancer Immunother Sci. 2013;342(6165):1432-1433.

    Not in our library10.1126/science.342.6165.1432

  58. 58.

    June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-1365.

    Not in our library10.1126/science.aar6711

  59. 59.

    Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355.

    Not in our library10.1126/science.aar4060

  60. 60.

    Wang C, Li M, Wei R, Wu J. Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma. J Bone Oncol. 2020;25:100332.

    Not in our library10.1016/j.jbo.2020.100332

Cited by papers we hold 5

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.